Home / Culture / Iran produces 8 epilepsy sustained-release tablets

Iran produces 8 epilepsy sustained-release tablets

'For the first time in Iran we have succeeded in producing edible sustained-release pharmaceuticals,' said Gholam Reza Akhavan Farid, Raha Pharmaceutical Company Managing Director on Saturday.

These products will save Iran from spending $ 30 million annually, according to Akhavan Farid who manages this knowledge-based company, located in the central Iranian city of Isfahan.

He said his company has sold more than 3.5 million dollars worth of Tegatard® (Carbamazepine 200 mg) and Rahakine® 200 (Sodium valproate) per year, meeting a major part of the country’s internal market. “All the company’s raw materials are produced in Iran,” Raha Pharmaceutical Company managing director stressed.

The pharmaceutical company, founded in 2008, has produced over 120 varieties of finished products such as tablets, capsules, pellets, ampules, eye drops, nasal sprays, syrups and semisolids (creams, gels and ointments) so far.

Sustained-release dosage forms are dosage forms designed to release a drug at a predetermined rate in order to maintain a constant drug concentration for a specific period of time with minimum side effects.

9218**2050

Follow us on Twitter @IrnaEnglish

www.irna.ir

Check Also

COVID-19 kills 148 Iranians over past 24 hours

Sima Sadat Lari said that, with the 148 new deaths, the country’s total COVID-19 death …